ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Exposure to the BRD4 inhibitor JQ1 sensitizes several leukemia cell lines but not the BCR/ABL1-positive chronic myelogenous leukemia cell line K562 [108].